Hello, everyone, and how are you this morning? We are doing just fine, thank you, despite another round of wintry temperatures enveloping the Pharmalot campus. Of course, we combat the chill by brewing a few cups of stimulation. Today, we are toggling between chocolate cherry decadence and butter pecan. Feel free to offer suggestions. Meanwhile, we have assembled the usual menu of tidbits to help you on your busy journey. We hope it goes well and you have a productive day. And, as always, do keep in touch …

AbbVie (ABBV) halted enrollment for a late-stage trial of a drug called Rova-T as a second-line therapy for advanced small-cell lung cancer after the medicine demonstrated shorter overall survival than a control arm, Reuters tells us. AbbVie acquired Rova-T through its $5.8 billion acquisition of Stemcentrx in 2016, as it aimed to enter the broad and lucrative arena of solid tumors and lessen dependence on its Humira arthritis treatment. But in March, AbbVie said it would not seek accelerated approval for the drug, a setback to its efforts to build its cancer drug pipeline.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • As for our scribes morning beverage “toggling,” I would opt for the much healthier (sounding) option of “Harvest Blueberry” which I am quaffing now … but who am I?

Your daily dose of news in health and medicine

Privacy Policy